EUCTR2014-003002-32-IT进行中（未招募）1 期
Open label study to evaluate the pharmacokinetics of fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects with Clostridium difficile Infection (CDI) - PROFILE
ASTELLAS PHARMA EUROPE LIMITED0 个研究点目标入组 25 人开始时间: 2021年5月27日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •¿ Subject is aged at least 18
- •¿ Confirmed diagnosis or history of IBD for at least 3 months
- •¿ CDI confirmed positive according to local standard testing for the
- •presence of C. difficile within 48 hr prior to enrolment.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •¿ Subject has received more than one day of dosing of any CDI therapy within the 48 hrs prior to enrolment
- •Presence of an ostomy or short bowel syndrome
- •Subject has a current diagnosis of toxic megacolon
- •Subject has previously participated in a CDI vaccine study
- •Subject has hypersensitivity to fidaxomicin or any of its components
研究者
相似试验
进行中（未招募）
1 期
A study in which the blood levels of the antibiotic fidaxomicin are studied in patients with an inflammation of the intestine and concomitantly an infection of the gut caused by bacteria called Clostridium difficile.EUCTR2014-003002-32-PLAstellas Pharma Europe Ltd.40
进行中（未招募）
1 期
A study in which the blood levels of the antibiotic fidaxomicin are studied in patients with an inflammation of the intestine and concomitantly an infection of the gut caused by bacteria called Clostridium difficile.Clostridium Difficile Infection (CDI) also known as C. difficile-associated diarrhoea (CDAD)MedDRA version: 19.0Level: LLTClassification code 10022661Term: Intestinal infection due to clostridium difficileSystem Organ Class: 100000004862EUCTR2014-003002-32-ATAstellas Pharma Europe Ltd.25
进行中（未招募）
1 期
A study in which the blood levels of the antibiotic fidaxomicin are studied in patients with an inflammation of the intestine and concommitantly an infection of the gut caused by bacteria called Clostridium difficile.EUCTR2014-003002-32-GRAstellas Pharma Europe Ltd.40
进行中（未招募）
1 期
A study in which the blood levels of the antibiotic fidaxomicin are studied in patients with an inflammation of the intestine and concomitantly an infection of the gut caused by bacteria called Clostridium difficile.Clostridium Difficile Infection (CDI) also known as C. difficile-associated diarrhoea (CDAD)MedDRA version: 18.0Level: LLTClassification code 10022661Term: Intestinal infection due to clostridium difficileSystem Organ Class: 100000004862EUCTR2014-003002-32-CZAstellas Pharma Europe Ltd.40
进行中（未招募）
1 期
A study in which the blood levels of the antibiotic fidaxomicin are studied in patients with an inflammation of the intestine and concommitantly an infection of the gut caused by bacteria called Clostridium difficile.Clostridium Difficile Infection (CDI) also known as C. difficile-associated diarrhoea (CDAD)MedDRA version: 18.0Level: LLTClassification code 10022661Term: Intestinal infection due to clostridium difficileSystem Organ Class: 100000004862EUCTR2014-003002-32-DEAstellas Pharma Europe Ltd.40